UCLA Expert for Macular Degeneration Coverage
Main Category: Eye Health / BlindnessArticle Date: 02 Feb 2005 - 21:00 PDT
Dr Christine Gonzales: An assistant professor of ophthalmology at the Jules Stein Eye Institute at UCLA, Dr Gonzales is an expert on age-related macular degeneration.
She was also the lead researcher in the clinical trials for Macugen, developed by Eyetech Pharmaceuticals and Pfizer Inc. for the treatment of AMD-the leading cause of vision loss in older patients in the developed world.
The U.S Food and Drug Administration approved Macugen on Dec. 17. Dr. Gonzales is available to speak with the media about macular degeneration, including causes and treatment options. She can also speak about Macugen, which targets vascular endothelial growth factor, a protein that triggers the abnormal blood vessel growth and leakage characteristic of the condition. Educated at UCLA and the University of California, San Francisco, where she earned her M.D., Dr. Gonzales is an expert in the treatment of macular degeneration and diabetic retinopathy, which can also be treated with the new drug. She has lectured throughout the world on macular degeneration and related topics. She has also published papers in the field's top journals, including Ophthalmic Epidemiology, the American Journal of Ophthalmology, and Ophthalmology.
924 Westwood Blvd., Ste. 350
Los Angeles, CA 90095
Phone 310-794-0777
Fax 310-794-2259
University of California, Los Angeles (UCLA), Health Sciences
Visit our eye health / blindness section for the latest news on this subject.
MLA
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/19550.php>
APA
http://www.medicalnewstoday.com/releases/19550.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Karen
posted by Karen Reese on 24 Dec 2010 at 6:14 pmI am writing regarding my fathers macular degeneration. He has wet in one eye and dry in the other. He is 85 years old, very active in his lifelong business of construction. It is imperative that he have his eyesight to read plans, etc. He has seen two eye docs, one who believed due to his perfect health that he would be a viable candidate for trial meds and one who discouraged him from further seeking same. Is there a certain criteria for candidates for clinical trials? It would be the gift of a lifetime for certain to regain even some measure of his sight back. He has adequate vision in one eye and they seem to have halted the progression however the other eye is degerating quickly. Please advise.
sincerely, Karen Reese
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




